Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?

PubWeight™: 0.79‹?›

🔗 View Article (PMC 3969251)

Published in Clin Interv Aging on March 24, 2014

Authors

Edelgard Anna Kaiser1, Ulrich Lotze2, Hans Hendrik Schäfer3

Author Affiliations

1: Roche Diagnostics International AG, Rotkreuz, Switzerland.
2: Department of Internal Medicine, DRK-Manniske-Krankenhaus Bad Frankenhausen, Bad Frankenhausen, Germany.
3: Roche Diagnostics International AG, Rotkreuz, Switzerland ; Institute of Anatomy II, University Hospital Jena, Friedrich-Schiller University, Jena, Germany.

Associated clinical trials:

Systolic Blood Pressure Intervention Trial (SPRINT) | NCT01206062

Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (ESH-CHL-SHOT) | NCT01563731

Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) | NCT00454662

Articles cited by this

(truncated to the top 100)

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 36.26

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA (2014) 34.12

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet (1998) 26.64

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ (2009) 17.73

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 10.05

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75

A systematic review of the associations between dose regimens and medication compliance. Clin Ther (2001) 9.23

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet (1999) 7.65

Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol (2008) 7.04

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ (2008) 6.13

Silent brain infarcts: a systematic review. Lancet Neurol (2007) 5.76

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 5.67

Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med (2013) 5.34

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91

European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98

Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet (1999) 3.81

Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA (1998) 3.37

Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19

Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) (2013) 2.94

Beta-blockers for hypertension. Cochrane Database Syst Rev (2012) 2.67

Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med (1988) 2.65

Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens (2010) 2.49

An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol (2013) 2.47

Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health (1996) 2.33

Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart (2013) 2.23

Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension (2005) 1.77

How far should blood pressure be lowered? N Engl J Med (1992) 1.76

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol (2010) 1.67

Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens (2009) 1.63

Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther (1998) 1.59

Age-related bias in the management of hypertension: a national survey of physicians' opinions on hypertension in elderly adults. J Gerontol A Biol Sci Med Sci (2002) 1.58

How applicable are clinical practice guidelines to elderly patients with comorbidities? Can Fam Physician (2011) 1.51

Blood pressure lowering in the oldest old. J Hypertens (2010) 1.40

Association between blood pressure and cognitive function in a biracial community population of older persons. Neuroepidemiology (2002) 1.36

Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) (2011) 1.34

Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke (2006) 1.33

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail (1999) 1.32

Barriers to hypertension control. Am Heart J (2005) 1.32

Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology (2013) 1.30

Protocol-based treatment of hypertension: a critical step on the pathway to progress. JAMA (2014) 1.30

The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens (1997) 1.28

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail (2011) 1.20

Blood pressure j-curve: current concepts. Curr Hypertens Rep (2012) 1.18

Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med (2010) 1.17

Performance-based financing in low- and middle-income countries: still more questions than answers. Bull World Health Organ (2012) 1.16

Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med (2012) 1.15

Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. Cardiovasc Diabetol (2009) 1.14

Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13

Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension (2011) 1.12

Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther (2010) 1.12

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens (2011) 1.09

Methods to measure patient compliance with medication regimens. J Pain Palliat Care Pharmacother (2004) 1.05

The "Child Health Evidence Week" and GRADE grid may aid transparency in the deliberative process of guideline development. J Clin Epidemiol (2012) 1.05

Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA (2014) 1.04

Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens (2012) 1.04

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens (2009) 1.00

Management of hypertension in the elderly. Nat Rev Cardiol (2012) 0.98

Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens (2013) 0.98

Sex differences in barriers to antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc (2013) 0.97

Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J (2004) 0.97

Recommendations for treating hypertension: what are the right goals and purposes? JAMA (2014) 0.96

Pharmacoeconomic challenges in disease management of hypertension. J Hypertens Suppl (2001) 0.95

What is an appropriate blood pressure goal for the elderly: review of recent studies and practical recommendations. Clin Interv Aging (2013) 0.95

Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol (2000) 0.94

Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail (2012) 0.94

Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int (2011) 0.93

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press (1998) 0.92

The j-point phenomenon in aggressive therapy of hypertension: new insights. Curr Atheroscler Rep (2012) 0.88

Hypertension in the elderly: some practical considerations. Cleve Clin J Med (2012) 0.88

The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension. Am J Cardiovasc Drugs (2006) 0.87

ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging (2010) 0.87

Assessing the trustworthiness of the guideline for management of high blood pressure in adults. JAMA (2014) 0.87

Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens (2012) 0.87

Blood pressure control and management of very elderly patients with hypertension in primary care settings in Spain. Hypertens Res (2013) 0.86

Blood pressure variability and risk of dementia in an elderly cohort, the Three-City Study. Alzheimers Dement (2013) 0.86

Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res (2011) 0.86

Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation. J Hum Hypertens (1999) 0.83

The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials. PLoS One (2013) 0.83

Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications. Drugs Aging (1993) 0.83

Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents. Curr Med Res Opin (2013) 0.82

The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. Can Pharm J (Ott) (2013) 0.82

The role of ACE inhibitors in the treatment of hypertensive elderly patients. Z Gerontol Geriatr (2000) 0.82

Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press (2007) 0.82

Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol (2010) 0.81

What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study. BMC Fam Pract (2012) 0.81

Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial. Age Ageing (2012) 0.81

Review of direct renin inhibition by aliskiren. J Renin Angiotensin Aldosterone Syst (2013) 0.81

Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs. J Am Med Dir Assoc (2013) 0.81

Current status of aggressive blood pressure control. World J Cardiol (2011) 0.81

Polypharmacy and adverse drug reactions in Japanese elderly taking antihypertensives: a retrospective database study. Drug Healthc Patient Saf (2013) 0.80

New-onset diabetes and antihypertensive treatment. GMS Health Technol Assess (2010) 0.79

The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease. Drugs Aging (2003) 0.79

Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens (2010) 0.79